deltatrials
Unknown PHASE3 NCT01995721

4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children

Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children

Sponsor: Merck Sharp & Dohme LLC

Conditions Recurrent Respiratory Papillomatosis
Interventions 4-valent HPV vaccine
Updated 6 times since 2017 Last updated: Nov 20, 2013 Started: Feb 28, 2014 Primary completion: Feb 28, 2017 Completion: Feb 28, 2017

A PHASE3 clinical study on Recurrent Respiratory Papillomatosis, this trial is ongoing. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  3. Jun 2022 — Jul 2024 [monthly]

    Unknown Status PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Unknown Status PHASE3

  5. Feb 2017 — Jan 2021 [monthly]

    Unknown Status PHASE3

    Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • National Institute of Child Health, Hungary
Data source: National Institute of Child Health, Hungary

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Budapest, Hungary